1972
DOI: 10.1210/jcem-35-5-768
|View full text |Cite
|
Sign up to set email alerts
|

THE INHIBITION OF PROLACTIN SECRETION IN MAN BY CB-154 (2-Br-α-ergocryptine)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

4
14
0
1

Year Published

1973
1973
1984
1984

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 193 publications
(19 citation statements)
references
References 0 publications
4
14
0
1
Order By: Relevance
“…RU 486 inhibition of PRL secretion occurred rapidly (<lh) and the response to a single dose was shortlived (<6h) compared with bromocriptine (9). Acute suppression of PRL by RU 486 confirmed and extended our previous reports upon the critical role of progesterone in the induction of hyperprolactineraia by sex steroids (4,6,10).…”
Section: Discussionsupporting
confidence: 80%
“…RU 486 inhibition of PRL secretion occurred rapidly (<lh) and the response to a single dose was shortlived (<6h) compared with bromocriptine (9). Acute suppression of PRL by RU 486 confirmed and extended our previous reports upon the critical role of progesterone in the induction of hyperprolactineraia by sex steroids (4,6,10).…”
Section: Discussionsupporting
confidence: 80%
“…It was thus necessary to carry out dynamic tests to estimate the stimulation or inhibition of secretion ; these tests used either TRH (thyrotropin-releasing hormone), known to release prolactin (Bowers et al, 1973 ;Jacobs et al, 1971), or rye ergot derivatives such as bromocriptine which inhibits prolactin secretion (Besser et al, 1972 ;Del Pozo et al, 1972).…”
mentioning
confidence: 99%
“…This rye ergot alkaloid inhibits the secretion of prolactin (Del Pozo et al, 1972), and its use in cases of hyperprolactinemia provokes the reappearance of the menstrual cycle in most cases (Besser et al, 1972 ;Del Pozo et al, 1974 ;Seki, Seki and Okumura, 1975 ;Fossati, Strauch and Tourniaire, 1976). Bromocriptine does not modify LH or FSH, but increases estradiol secretion (Seppala et al, 1976 …”
mentioning
confidence: 99%
“…This is indirectly proved by a decrease of HVA in the CSF (14). This same direct stimulating action of bromocryptine on postsynaptic dopamine receptors may be re sponsible for the unequivocally therapeutic activity of bromocryptine in a variety of hypothalamic/pituitary endocrinological diseases (8,10,13,15). The postsynaptic activity of bromocryptine also involves dopamine re ceptors in the mesolimbic system (mental changes), and dopamine receptors outside the blood brain barrier: the area postrema (nausea), and tire autonomic nervous system (hypoten sion) (19).…”
Section: Discussionmentioning
confidence: 80%